VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

(2022) Nora Berois et al.   Cancers

Combined Analysis of Multiple Glycan-Array Datasets: New Explorations of Protein–Glycan Interactions

(2021) Zachary Klamer et al.   ANALYTICAL CHEMISTRY

Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer

(2020) Sundee Dees et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2

(2020) Ali Adel Dawood et al.   MICROBIAL PATHOGENESIS

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia

(2019) Dennis C. Harrer et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges

(2019) Dennis C. Harrer et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

(2018) Kristina M. Ilieva et al.   Frontiers in Immunology

Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology

(2018) Ji Hee  Lee et al.   PATHOBIOLOGY

Inhibition of N-glycosylation by tunicamycin attenuates cell–cell adhesion via impaired desmosome formation in normal human epidermal keratinocytes

(2018) Seon-Pil Jin et al.   BIOSCIENCE REPORTS

Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration

(2017) Amy Winship et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects

(2017) Laura F. Hutchins et al.   Oncotarget

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer

(2015) Pier Andrea Nicolosi et al.   Theranostics

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

(2014) Rachel E Beard et al.   Journal for ImmunoTherapy of Cancer

T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

(2013) C. Geldres et al.   CLINICAL CANCER RESEARCH

CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma

(2012) Z. Rivera et al.   CLINICAL CANCER RESEARCH

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma

(2011) Matthew A. Price et al.   Pigment Cell & Melanoma Research

CSPG4 in Cancer: Multiple Roles

(2010) X. Wang et al.   CURRENT MOLECULAR MEDICINE

CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer

(2010) Xinhui Wang et al.   JNCI-Journal of the National Cancer Institute

Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies

(2008) Allison S. Drake et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY